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A B S T R A C T
Background: Although the cause of acute eosinophilic pneumonia (AEP) has not yet been fully clarified, cigarette
smoking is reported to be a risk factor for developing AEP. The heat-not-burn cigarette (HNBC) was developed to
reduce the adverse effects of smoke on the user's surroundings. However, the health risks associated with HNBCs
have not yet been clarified. We report a successfully treated case of fatal AEP presumably induced by HNBC use.
Presentation of case: A 16-year-old man commenced HNBC smoking two weeks before admission and subse-
quently suffered from shortness of breath that gradually worsened. The patient was transferred to emergency
department and immediately intubated because of respiratory failure. Computed tomography showed mosaic
ground-glass shadows on the distal side of both lungs with a PaO2/FIO2 ratio of 76. The patient required veno-
venous extracorporeal membrane oxygenation (ECMO) for severe respiratory failure. He was diagnosed with
AEP by clinical course and detection of eosinophils in sputum; thus, methylprednisolone was administrated. The
patient was weaned off ECMO four days after initiation and extubated the day after. He fully recovered without
sequelae.
Conclusion: As far as we know, our patient is the first case of AEP induced by HNBC use successfully treated with
ECMO. Emergency physicians must be aware that HNBCs can induce fatal AEP.
1. Background
Acute eosinophilic pneumonia (AEP), an uncommon but important
cause of severe respiratory failure, is usually triggered by inhalation of
allergic antigens such as chemical substances and fungi [1]. Cigarette
smoking in particular is a well-known cause of AEP, as the condition
normally happens within a few weeks after starting smoking [2].
The heat-not-burn cigarette (HNBC) was developed to reduce the
negative effects of smoke on the user's surroundings and has been on
the market since 2014 in Japan. HNBC use has spread worldwide; 4.7%
of all cigarette smokers in Japan used HNBCs in 2017 according to an
internet survey [3]. HNBCs are widely believed to expose smokers and
their surroundings to lesser amounts of toxic substances such as nico-
tine compared to conventional cigarettes [4]; however, the latest re-
search shows the amount of nicotine released by HNBCs is almost equal
to that released by conventional cigarettes [5]. Furthermore, the health
risks associated with HNBCs have not yet been clarified.
Herein, we report a case of fulminant HNBC-induced AEP success-
fully treated with extracorporeal membrane oxygenation (ECMO). Only
one report of HNBC-induced AEP has been published previously as far
as we know [6]. Since HNBC use has been recently increasing, emer-
gency physicians should consider HNBC smoking as one of the sig-
nificant causes of AEP. Our experience may help emergency physicians
determine the cause of AEP.
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A 16-year-old man with a history of crustacea allergy and bronchial
asthma in childhood was transferred to emergency department (original
hospital) with complaints of severe cough, fatigue, and shortness of
breath. These symptoms started immediately after smoking HNBCs and
worsened in the two weeks before hospitalization.
His Glasgow Coma Scale score at presentation indicated health de-
terioration (E1V3M5). His vital signs were as follows: blood pressure
109/50mmHg, heart rate 136 bpm, respiratory rate 30 breaths per
minute, body temperature 37.3 °C, and oxygen saturation of pulse
oximetry (SpO2), 81%. Blood test results revealed leukocytosis (white
blood cell count of 28000/μL; neutrophils 98%, lymphocytes 1.5%,
eosinophils 0%, monocytes 0.5%) and an increase of C-reactive protein,
32.3 mg/dL. Renal function and liver enzymes were unremarkable:
blood urea nitrogen 17.1 mg/dL, serum creatinine 0.67 mg/dL, aspar-
tate aminotransferase 11 U/L, and alanine aminotransferase 8U/L, with
increased lactic acid levels of 2.0 mmol/L. Toxicological screening was
negative.
Both lungs showed a ground-glass appearance in the chest X-ray and
computed tomography (CT) showed consolidation spreading in a mo-
saic pattern from the middle to distal side of both lungs (Fig. 1). Based
on the patient's clinical course and CT findings, he was strongly sus-
pected of having AEP, and 500mg of methylprednisolone (mPSL) was
administered.
Since oxygen therapy was ineffective, the patient was intubated and
mechanical ventilation started. On the day after, his respiratory status
was deteriorated and he was transferred to our hospital for further
treatment. The ventilation settings at our hospital admission were a
fraction of inspiratory oxygen (FIO2) of 1.0, respiratory frequency of 15
breaths per minute, positive end-expiratory pressure (PEEP) of 15
cmH2O, and plateau pressure (Pplat) of 30 cmH2O. Blood gas analysis
under this setting showed a pH of 7.188, pO2 of 76mmHg, pCO2 of
79.3 mmHg, base excess −1.8mmHg. A bloody foamy secretion oozed
out of the tracheal tube. At that time, the PaO2/FIO2 ratio (PFR) was 76,
that satisfied a criterion for severe ARDS in Berlin definition [7]. We
continued the conventional ventilation; however, no improvement was
found.
We subsequently initiated veno-venous (VV) ECMO by 23 french
38cm drainage cannula inserted at the right jugular vein and 20 french
15cm infusion cannula inserted at the right femoral vein with 4.0 L per
minute of blood flow. We adjusted the ventilator settings to 0.4 of FIO2,
10 cmH2O of PEEP, and 20 cmH2O of Pplat for resting lung. The pa-
tient's lung totally collapsed and he had no tidal volume at that time
(Supplementary Fig. a and b).
To make an accurate diagnosis, we examined sputum cytology of
tracheal secretions instead of bronchoalveolar lavage (BAL) fluid after
ECMO initiation. The cytological findings showed that aggregated eo-
sinophils were accumulating and the percentage of eosinophils, neu-
trophils, and lymphocytes were 14.7%, 51.7%, and 33.6%, respectively
(Fig. 2). 1000mg of mPSL was administrated intravenously for three
days, followed by 60mg of oral prednisolone. Tidal volume started to
increase on the fourth hospital day and oxygenation and carbon dioxide
emission were gradually recovered (Fig. 3). ECMO was removed on the
fifth hospital day. The patient was extubated on the sixth hospital day
and transferred back to the original hospital on the 10th day. Blood
tests showed the number of eosinophils had increased from the fifth
hospital day up to 2980/μL on the seventh day (Fig. 3). Chest x-ray and
CT findings on the ninth hospital day showed that the alveolar con-
solidation had disappeared and showed a healthy alveolar structure in
both lungs (Supplementary Fig. c and d).
After transferring back to the original hospital, the patient re-
habilitated in the general ward. Oral prednisolone was gradually
Fig. 1. CT findings at emergency department. Non-contrast CT scan was per-
formed using slice thickness 5 mm. The picture shows ground-grass findings
spreading in both lungs. Such infiltrative shadows spread diffusely from the
apex of each lung to above the diaphragm.
Fig. 2. Sputum cytology on the first hospital day. The picture shows aggrega-
tion of eosinophils (arrows). The percentage of eosinophils increased slightly
(14.7%). Many neutrophils were present (51.7%).
Fig. 3. Clinical course. On the first day, the patient had little tidal volume.
ECMO was needed for four days and the tidal volume (blue bar) increased
gradually with administration of methylprednisolone. Interestingly, although
blood tests showed no eosinophils on the first day, the elevation of eosinophils
(orange line) reached 2980/μL on the seventh day.
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decreased and stopped. The patient was discharged without sequelae 10
days after transferring. Currently, the patient is well enough to lead a
normal life. The patient and his family were told to never smoke again,
not even HNBCs.
3. Discussion
To draw health-conscious smokers and revamp smoking's public
image, “safer” products such as HNBCs have been developed. HNBC use
has been increasing in recent years due to the absence of smoke and its
adverse effects on the user's surroundings. It is widely believed that
HNBC users inhale less tar and accordingly, incur less harmful effects on
their health than with smoking conventional cigarettes. However,
previous studies have demonstrated that HNBCs' benefits are con-
troversial [5,6]. Conflicts of interests may have influenced the en-
dorsement of these devices in the past, since tobacco companies pro-
mote cigarette smoking while globally undermining tobacco control.
Health professionals and scholarly journals should consider both the
ethics and conflicts of interest associated with advocating tobacco
product substitution.
AEP can develop soon after initiation of smoking as well as re-
challenge with smoking after a long abstinence [2]. The mechanism of
how smoking causes AEP has not been clarified; however, some che-
mical substances contained in the cigarette could contribute to acti-
vating an allergic reaction and eosinophils. In the mechanism of allergic
reaction, the theory that “if the amount of toxic substance is small, the
risk proportionally decreases” is not necessarily true. Auer reported that
HNBCs release nicotine in the almost same amount, 4–82% of volatile
organic compounds, and 0.1–9% polycyclic aromatic hydrocarbons as
conventional cigarettes [5]. Notably, HNBCs release more ace-
naphthene, one of the polycyclic aromatic hydrocarbons, compared to
conventional cigarettes [5].
AEP is marked by acute febrile respiratory failure associated with
pulmonary eosinophilia and diffuse radiographic infiltrates. The diag-
nostic criteria for AEP include: acute onset of symptoms seven days or
less before presentation; fever ≥37.2 °C; bilateral infiltrates on chest
film; severe hypoxemia: partial pressure of arterial oxygen (PaO2) on
room air ≤60, SpO2 on room air< 90%, or alveolar-arterial gra-
dient> 40; lung eosinophilia: BAL differential with ≥25% eosinophils
or predominance of eosinophils on open lung biopsy; and no history of
drug hypersensitivity, no historical or laboratory evidence of infection,
and no other known origin of acute eosinophilic lung disease [8,9].
While eosinophils are found in very few numbers, usually less than
2% in BAL in a normal lung, the percentage of eosinophils was 14.6% in
sputum cytology with aggregations in our patient, which did not meet
the criteria for AEP (Fig. 2). We made the final diagnosis of AEP based
on other criteria, even though our patient did not meet the BAL criteria.
It is also important to exclude other differential diagnoses, such as
bacterial pneumonia, viral pneumonia, vasculitis, autoimmune disease,
leukemia and lymphoma. We performed possible pathogen examina-
tions (culture, serological diagnosis etc.), examinations of vasculitis,
autoimmune diseases, leukemia and lymphoma; however, these tests
were all negative. Furthermore, our patient rapidly and dramatically
improved after administration of mPSL, which is typical with AEP [10].
It is reported that 75% of AEP in the acute phase does not show ele-
vation in the number of eosinophils in the blood [1]; however, it may
increase in the recovery phase of the second to eighth day after onset
[10]. In our case, there was no elevation of eosinophils in the acute
phase, and it increased to 2980/μL on the seventh hospital day. This is
considered a key finding for AEP diagnosis.
As far as we know, only one report of HNBC-induced AEP has pre-
viously been published [6]. In that case, the symptoms developed six
months after starting HNBC use. The patient required oxygen therapy
but not invasive ventilation. We report a successfully treated case of
fulminant HNBC-induced AEP where lung function deteriorated rapidly
and heavily, eventually requiring invasive ventilation.
Our case showed more rapid and massive progression compared to
the previous report [6], and VV ECMO was required. In this case, the
PFR of less than 80 persisted for more than 6 hours, that fulfills the
criteria for ECMO initiation in EOLIA study [11]. We performed VV
ECMO with the right jugular vein drainage and femoral vein infusion,
that is the normal method in our department. Previous studies indicate
that drainage from IVC realizes less recirculation and therefore the
route from the IVC to the right atrium is the standard in most centers
regarding VV ECMO with two cannulas. However, recent study has
shown that recirculation can be minimized by using multistage drai-
nage cannula through the right internal jugular vein with infusion to
the femoral vein [12].
Currently, two cases of AEP have been reported (including our re-
port), despite the short time period HNBCs have been on the market and
limited HNBC use. It is suggested that the incidence of AEP caused by
HNBC is equal to or greater than that caused by conventional cigarettes.
This implies that HNBCs can cause a rapid and fatal respiratory failure
requiring ECMO. Since AEP is reversible and usually improves in a short
time with administration of corticosteroid, VV ECMO should be em-
ployed if the patient's life cannot be maintained by conventional me-
chanical ventilation [13].
4. Conclusion
Our experience may suggest that HNBCs possibly induce fatal AEP.
Since this is only a case report, adverse effects and health risks cannot
be compared between HNBC and conventional cigarette use. A large-
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